Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937687 · ClinicalTrials.gov registry record · Early Phase 1
The Effects of a Combination of TeaCrine®, Dynamine, and Caffeine in Law Enforcement
A Early Phase 1 study, sponsored by University of South Carolina.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 49
- Enrollment target
NCT03937687: Completed Early Phase 1 study, sponsored by University of South Carolina.
NCT03937687 is a Early Phase 1 study that has completed, run by University of South Carolina. The registered enrollment target is 49 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03937687, a Early Phase 1 study, has completed, sponsored by University of South Carolina.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this randomized, placebo-controlled, three-condition, double-blind, between-subjects clinical trial is to determine and compare the effects of the combination of TeaCrine®, Dynamine, and caffeine to a placebo and caffeine condition on reaction time and target acquisition and accuracy. A secondary purpose is to observe the changes in hemodynamic variables in response to this combination.
Primary Outcome
Spatial reaction
Interventions
- DRUG Placebo
- DRUG Caffeine
- DRUG Caffeine+TeaCrine+Dynamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-05-04 |
| Est. Completion | 2020-11-15 |
| Phase | Early Phase 1 |
What the finished NCT03937687 record still lists
NCT03937687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03937687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03937687 about?
NCT03937687 is a clinical study titled "The Effects of a Combination of TeaCrine®, Dynamine, and Caffeine in Law Enforcement". The purpose of this randomized, placebo-controlled, three-condition, double-blind, between-subjects clinical trial is to determine and compare the effects of the combination of TeaCrine®, Dynamine, and caffeine to a placebo and caffeine condition on reaction time and target acquisition and accuracy....
What is the current status of trial NCT03937687?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 49 participants. The study started on 2019-05-04. Estimated completion is 2020-11-15.
What interventions are being tested in trial NCT03937687?
The interventions under investigation include: Placebo (DRUG), Caffeine (DRUG), Caffeine+TeaCrine+Dynamine (DRUG).
Who is sponsoring clinical trial NCT03937687?
This trial is sponsored by University of South Carolina, which has 157 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03937687's enrollment target sits among peer trials
49 534th of 2000 higher than 1,460 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI